Verrica Pharmaceuticals Inc (VRCA) COO Acquires $31,590.00 in Stock
Verrica Pharmaceuticals Inc (NASDAQ:VRCA) COO Linda Palczuk bought 3,000 shares of Verrica Pharmaceuticals stock in a transaction that occurred on Wednesday, January 16th. The shares were acquired at an average cost of $10.53 per share, for a total transaction of $31,590.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of NASDAQ:VRCA opened at $10.42 on Friday. Verrica Pharmaceuticals Inc has a 1 year low of $6.44 and a 1 year high of $23.29.
Verrica Pharmaceuticals (NASDAQ:VRCA) last announced its earnings results on Wednesday, November 7th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by ($0.03). As a group, equities research analysts anticipate that Verrica Pharmaceuticals Inc will post -1.17 earnings per share for the current year.
A number of large investors have recently made changes to their positions in the stock. FMR LLC bought a new stake in Verrica Pharmaceuticals in the 2nd quarter worth about $21,703,000. Laurion Capital Management LP purchased a new position in Verrica Pharmaceuticals in the second quarter worth about $395,000. Gilder Gagnon Howe & Co. LLC boosted its position in Verrica Pharmaceuticals by 12.4% in the third quarter. Gilder Gagnon Howe & Co. LLC now owns 167,574 shares of the company’s stock worth $2,723,000 after purchasing an additional 18,530 shares during the last quarter. Asymmetry Capital Management L.P. boosted its position in Verrica Pharmaceuticals by 28.1% in the third quarter. Asymmetry Capital Management L.P. now owns 76,885 shares of the company’s stock worth $1,249,000 after purchasing an additional 16,885 shares during the last quarter. Finally, Bank of New York Mellon Corp purchased a new position in Verrica Pharmaceuticals in the third quarter worth about $195,000. 32.07% of the stock is currently owned by institutional investors.
About Verrica Pharmaceuticals
Verrica Pharmaceuticals Inc develops and commercializes dermatological treatments in the United States. The company is advancing its lead product VP-102, a proprietary topical therapy, in various common skin indications, including Molluscum contagiosum and Verruca Vulgaris. It is also developing 2 Phase 3 trials in molluscum contagiosum under NCT03377803 and NCT03377790.
Read More: Net Income
Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.